0001628280-26-031638
SEC filingBD reported Q2 FY2026 revenue of $4.7 billion, up 5.2% reported and 2.6% FXN, with adjusted diluted EPS of $2.90, raised full-year adjusted EPS guidance, and executed $2.0 billion ASR and $2.1 billion debt retirement.
BD delivered Q2 FY2026 results ahead of expectations, with revenue of $4.7 billion growing 5.2% as reported and 2.6% on a foreign currency neutral basis, driven by broad-based execution where over 90% of the business achieved mid-single-digit growth. Key segments showed strength: Medical Essentials up 4.7% reported, Connected Care 4.9%, and Interventional 7.3%, while U.S. revenues rose 5.1% and international 5.5% reported despite FX headwinds. Adjusted diluted EPS of $2.90 increased 3.9% reported, reflecting margin momentum from BD Excellence initiatives and growth platforms. GAAP EPS was negative at $(0.13), impacted by items outside ordinary operations. CEO Tom Polen highlighted disciplined execution of the New BD strategy post the February 9, 2026 spin-off of the Biosciences and Diagnostic Solutions business to Waters, with results now reflecting continuing operations across four segments. Capital allocation included a $2.0 billion accelerated share repurchase and $2.1 billion debt retirement, underscoring commitment to shareholder returns. Based on first-half performance and improved visibility, BD raised full-year adjusted EPS guidance to $12.52-$12.72 from prior $12.35-$12.65 while reaffirming low single-digit revenue growth expectations. Recent highlights include launches like BD CentroVena One Insertion System, Pyxis Pro in Europe, and CE Markings for Revello Vascular Stent and Liverty TIPS Stent Graft, plus partnerships enhancing connected care with AI and robotics. These initiatives support margin expansion and long-term value creation.